On March 17, 2022, Don Kalkofen, the Chief Financial Officer of Protagonist Therapeutics, Inc. (the Company), submitted his notice of resignation from his position as Chief Financial Officer of the Company to be effective on April 1, 2022. Upon his resignation, Mr. Kalkofen will cease to serve as the Company's principal financial and accounting officer. The Company has initiated a search for a replacement for Mr. Kalkofen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.83 USD | +2.94% | +9.65% | +64.98% |
03/07 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000 | CI |
03/07 | Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.98% | 2.16B | |
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen as Principal Financial and Accounting Officer